<description>&lt;p&gt;&lt;span style= "font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-latin;"&gt; Bioxcel Therapeutics Inc.'s phase III results in bipolar disorders or schizophrenia could bring Igalmi (BXCL-501) out of the clinic and into patients' homes for easier treatment. Vimal Mehta, Bioxcel CEO, talks about the potential with Lee Landenberger in the latest BioWorld Insider podcast.&lt;/span&gt;&lt;/p&gt;</description>

The BioWorld Insider Podcast

BioWorld

Trying this at home: Bioxcel steps closer to an sNDA for Igalmi – AUDIO

AUG 29, 20259 MIN
The BioWorld Insider Podcast

Trying this at home: Bioxcel steps closer to an sNDA for Igalmi – AUDIO

AUG 29, 20259 MIN

Description

Bioxcel Therapeutics Inc.'s phase III results in bipolar disorders or schizophrenia could bring Igalmi (BXCL-501) out of the clinic and into patients' homes for easier treatment. Vimal Mehta, Bioxcel CEO, talks about the potential with Lee Landenberger in the latest BioWorld Insider podcast.